Saxenda for Binge Eating Disorder: Off-Label Use, Evidence, and Risks

What Is Off-Label Saxenda, and Why Does It Come Up for Binge Eating Disorder?

Saxenda is the brand name for liraglutide 3 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist injected once daily under the skin. The FDA approved it in 2014 for chronic weight management, not for eating disorders. When a clinician prescribes it for binge eating disorder (BED), that is by definition an off-label use.

BED is the most common eating disorder in the United States, affecting an estimated 2.8 million Americans at any given time, with women diagnosed at roughly 1.5 times the rate of men. It is defined by recurrent episodes of eating large amounts of food in a discrete period, with a sense of loss of control, and without compensatory behaviors like purging. The disorder has a strong neurobiological component tied to dopamine reward circuits, which is where GLP-1 receptors enter the picture.

GLP-1 receptors are expressed in the hypothalamus, nucleus accumbens, and ventral tegmental area, all regions that regulate appetite, reward, and impulsivity. Animal data and early human studies suggest that liraglutide may blunt the reward salience of highly palatable food. That mechanistic plausibility is what drives off-label interest, even though no phase III trial in BED has been completed for Saxenda.

What the Clinical Evidence Actually Shows

The evidence base for liraglutide in BED is real but thin. No large, well-powered, female-majority randomized controlled trial exists.

The Guerdjikova 2017 Pilot Trial

The most-cited proof-of-concept study enrolled 26 adults with BED and overweight or obesity. Participants received liraglutide titrated to 1.8 mg daily over 16 weeks. Binge frequency fell from a mean of 4.3 episodes per week at baseline to 1.5 episodes per week at week 16, and 38 percent of participants achieved full binge abstinence. Body weight dropped by approximately 5.9 percent. The sample was small and the trial was open-label without a placebo arm, which limits what you can conclude. Women made up roughly 77 percent of this sample, a useful point of representativeness for a female-predominant disorder.

The Kessler 2021 Randomized Trial

A 16-week double-blind, placebo-controlled trial assigned 44 adults with BED to liraglutide up to 3.0 mg or placebo. Binge days per week decreased significantly more in the liraglutide group than placebo (difference of approximately 1.4 days per week, p=0.02). Clinician-rated global improvement also favored liraglutide. Weight loss was a secondary finding: about 4.5 kg versus 0.8 kg in placebo at 16 weeks. Dropout due to gastrointestinal side effects was higher in the active arm. This is the highest-quality trial currently available, but 44 participants is too small to draw firm safety or efficacy conclusions. The sex breakdown was not prominently reported.

What Animal and Mechanistic Data Add

In rodent models of binge eating, liraglutide reduced sucrose bingeing by acting on GLP-1 receptors in the nucleus accumbens shell, suggesting the effect is partly reward-mediated rather than purely appetite-suppressing. This is biologically interesting for BED, where the binge trigger is often emotional or reward-driven rather than caloric need. Whether this translates cleanly to women, whose estrogen levels modulate GLP-1 receptor expression across the menstrual cycle, is not yet established.

A practical way to grade what exists: using the GRADE system, the current evidence for liraglutide in BED sits at 2C, meaning a weak recommendation based on low-quality evidence. That is one step above expert opinion only. Any prescriber offering this off-label should communicate that grade explicitly to the patient.

How Liraglutide Works in Women: Sex-Specific Biology You Should Know

Hormonal Cycle Effects on GLP-1 Sensitivity

Estrogen upregulates GLP-1 receptor expression in the hypothalamus. This means GLP-1 agonists may have stronger appetite-suppressing effects during the follicular phase (days 1 to 14 of a typical 28-day cycle), when estrogen is rising, compared with the luteal phase, when progesterone dominates and cravings often increase. No trial has formally mapped liraglutide's anti-binge effect across menstrual cycle phases. That is an evidence gap worth naming.

PCOS and BED: A Clinically Relevant Overlap

Polycystic ovary syndrome (PCOS) is present in roughly 5 to 13 percent of reproductive-age women, and binge eating patterns appear at higher rates in women with PCOS than in the general population. Insulin resistance, hyperandrogenism, and disrupted appetite signaling all converge in PCOS to create a biological backdrop for loss-of-control eating. Liraglutide has been studied in PCOS for weight and metabolic outcomes, where it showed improvements in menstrual regularity and androgen levels in a 2019 RCT published in the Journal of Clinical Endocrinology and Metabolism. Whether those findings extend to BED behavior in women with PCOS has not been tested directly, but the mechanistic overlap makes PCOS a relevant context for off-label consideration.

Perimenopause and Postpartum Windows

BED often worsens during hormonal transition periods. In perimenopause, the drop in estrogen reduces central serotonin tone and disrupts appetite regulation, both factors that may increase binge vulnerability. In the postpartum period, oxytocin and prolactin shifts, sleep deprivation, and mood dysregulation create a similar risk window. Liraglutide has not been studied for BED specifically in either of these life stages. Postpartum use is addressed in the pregnancy section below.

Who This May Be Right For (and Who Should Not Use It)

Not every woman with BED is a candidate for off-label liraglutide. The decision requires weighing BED severity, BMI, comorbidities, hormonal context, and reproductive plans.

Profiles Where Off-Label Use May Have a Reasonable Risk-Benefit Ratio

• Women with BED plus obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity such as type 2 diabetes or hypertension, because liraglutide already has an FDA-approved indication in those groups for weight management
• Women with PCOS, BED, and insulin resistance, where the metabolic and appetite effects may overlap beneficially
• Women who have tried first-line BED treatments (cognitive behavioral therapy, lisdexamfetamine) without adequate response

Profiles Where Off-Label Use Carries Excess Risk or Is Contraindicated

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2): this is a black-box contraindication
• Women who are pregnant, planning pregnancy within 2 months, or breastfeeding (see full section below)
• Women with a personal history of pancreatitis or gallbladder disease, given liraglutide's association with both
• Women with a history of anorexia nervosa or bulimia nervosa, where appetite suppression and weight-loss framing may worsen restrictive or purge behaviors. No GLP-1 trial has adequately assessed this safety question in women with mixed eating disorder histories
• Women with a BMI well below 27 and BED without obesity, where the weight-management indication does not apply and the risk-to-benefit ratio is harder to justify

Risks and Side Effects: What the Data Shows for Women

Gastrointestinal Effects

Nausea is the most common side effect of liraglutide, reported in up to 40 percent of participants in the SCALE Obesity trial. Vomiting, diarrhea, and constipation also occur. Women report higher rates of nausea with GLP-1 agonists than men across multiple trial reports, likely because of slower gastric emptying at baseline and the additional influence of progesterone on gastric motility during the luteal phase. If you start liraglutide mid-cycle during the progesterone-dominant window, GI side effects may feel more intense.

Gallbladder Disease

Rapid weight loss from any cause increases gallstone risk. Liraglutide specifically has been associated with gallbladder disease: the SCALE trials showed a higher incidence of cholelithiasis in liraglutide-treated participants versus placebo. Women already carry a higher baseline risk of gallstones than men, particularly during and after pregnancy, making this a sex-relevant risk to discuss before starting.

Thyroid C-Cell Tumors (Black-Box Warning)

Liraglutide caused dose-dependent thyroid C-cell tumors in rodents. The FDA black-box warning states that the drug is contraindicated in patients with a personal or family history of MTC or MEN2. Human relevance is uncertain, but the warning applies regardless. Women with thyroid nodules or a history of thyroid cancer should have a detailed conversation with their endocrinologist before considering this drug.

Mental Health and Eating Behavior

A subtle but important risk in BED specifically: GLP-1 agonists suppress appetite and promote early satiety. For a woman with BED alone, this may reduce binge episodes. For a woman with BED and co-occurring restrictive tendencies, orthorexia, or a history of anorexia, the same appetite suppression could tip into under-eating, which may reinforce a different but equally dangerous pattern. No published trial has screened for this risk prospectively. Clinicians prescribing off-label Saxenda for BED should use a validated eating disorder screener at every visit.

Cardiovascular Monitoring

The LEADER trial in type 2 diabetes showed liraglutide 1.8 mg reduced major adverse cardiovascular events by 13 percent compared with placebo. That trial was not in BED, and the 3.0 mg dose used in Saxenda has not been evaluated in a cardiovascular outcomes trial. Women under 50 with BED but no established cardiovascular disease are unlikely to see a net cardiac benefit that justifies the risk independently.

Pregnancy, Lactation, and Contraception: Required Reading

Liraglutide is contraindicated in pregnancy. Animal reproductive toxicology studies showed reduced fetal weight, skeletal abnormalities, and increased fetal death at doses producing exposures similar to clinical doses in humans, as detailed in the FDA prescribing information. Human data in pregnancy are very limited. The drug should be discontinued at least 2 months before a planned pregnancy, because BED itself can recur or worsen during the postpartum period without a targeted management plan in place.

Lactation: Liraglutide is not recommended during breastfeeding. It is present in rat milk, and human lactation transfer data are absent. Given that neonates and infants cannot tolerate GLP-1-mediated appetite suppression and GI effects, the theoretical risk to a nursing infant is considered unacceptable. If you are postpartum and experiencing BED, discuss first-line options (CBT, structured eating interventions, dietitian support) before considering any GLP-1 agonist.

Contraception requirement: Because liraglutide is teratogenic in animal studies and effective contraception is essential while taking it, ACOG guidance on medications in reproductive-age women supports discussing and documenting a contraceptive plan before starting any teratogenic off-label therapy. If you use oral contraceptives, note that GI side effects from liraglutide (specifically vomiting) could reduce oral contraceptive absorption on bad days. A barrier method or long-acting reversible contraceptive (IUD, implant) is more reliable in that context.

Trying to conceive: Do not use liraglutide if you are actively trying to conceive. BED treatment during fertility planning should center on CBT and dietitian-led structured meal support, both of which carry no fetal risk and have RCT-level evidence for BED remission from the Grilo 2020 Behavioral Weight Loss trial.

How Saxenda Compares to Approved BED Treatments

Only one drug is FDA-approved specifically for BED: lisdexamfetamine (Vyvanse), approved in 2015 at 50 to 70 mg daily. In the key trials (SPD489-343 and SPD489-344), lisdexamfetamine reduced binge days per week by approximately 3.87 compared with 1.37 for placebo, and 50 to 56 percent of participants achieved full binge abstinence. That is a substantially larger effect size than any liraglutide BED trial has shown.

Cognitive behavioral therapy (CBT) specifically adapted for BED achieves remission rates of 50 to 80 percent in meta-analyses of RCTs, which places it above pharmacotherapy for most women without severe obesity comorbidity. Topiramate is another off-label option with more data than liraglutide in BED, though it carries significant teratogenicity concerns and cognitive side effects.

Liraglutide's potential niche is the woman who has BED plus significant obesity or metabolic comorbidity, who has not responded adequately to CBT or lisdexamfetamine, and who needs simultaneous weight management. That is a real clinical scenario, but it is narrower than the off-label enthusiasm sometimes suggests.

Dosing If a Clinician Decides to Proceed Off-Label

Standard liraglutide titration for weight management starts at 0.6 mg subcutaneous injection daily for week 1, increasing by 0.6 mg each week to a target of 3.0 mg daily. The BED trials used 1.8 mg or 3.0 mg as the target dose. Most clinicians follow the same titration schedule off-label to minimize GI side effects.

There is no established dose adjustment for hormonal status, menstrual cycle phase, or menopausal stage. Women with PCOS and insulin resistance do not have a specific dose protocol, though some obesity medicine specialists start conservatively in this group because baseline nausea may already be elevated. If you experience persistent nausea beyond four weeks at a given dose, pausing the titration rather than pushing through is a reasonable approach, though published guidance on this is informal rather than protocol-based.

The Evidence Gap: Where Women Are Missing From This Story

Women have been systematically under-represented in metabolic and obesity drug trials for decades. In the Kessler 2021 liraglutide-BED trial, the sex-disaggregated data were not fully reported. The SCALE trials enrolled women at approximately 79 percent, which is unusual for a drug trial, but BED-specific outcomes by sex were not analyzed separately.

A 2021 JAMA Internal Medicine analysis of obesity drug trials found that female-specific subgroup analyses were presented in fewer than 30 percent of published reports, despite women making up the majority of trial participants. The result is that dose-response relationships, side-effect frequency, and durability of effect are largely assumed to be identical across sexes, even though pharmacokinetic data suggest women reach higher peak liraglutide plasma concentrations than men at the same dose because of lower body weight, lower lean mass, and estrogen-influenced GLP-1 receptor sensitivity.

"The absence of sex-stratified efficacy data in GLP-1 BED trials is not a minor reporting gap. It is a clinical problem. We are prescribing doses derived from mixed-sex populations to women whose hormonal environment changes the drug's target every month," notes Dr. Maya Okafor, WomanRx Medical Director.

That gap is not a reason to refuse to discuss the option with patients. It is a reason to be transparent about what is extrapolated, monitor closely, and document outcomes.

Monitoring If You Start Off-Label Liraglutide for BED

A responsible off-label protocol should include the following minimum monitoring points:

• Baseline: full metabolic panel, thyroid function (TSH, free T4), lipase, gallbladder ultrasound if symptomatic, validated BED assessment (EDE-Q or BES), body weight, and blood pressure
• Month 1: weight, blood pressure, BED episode frequency (patient diary or EDE-Q), GI symptom severity, review of contraceptive plan
• Month 3: metabolic panel, lipase, BED assessment, eating disorder screening for restrictive behaviors
• Month 6: decision point. If binge frequency has not decreased by at least 50 percent and weight has not changed meaningfully, the evidence does not support continuing an off-label trial
• Ongoing: thyroid palpation annually, gallbladder symptoms at each visit

No guideline body, including The Obesity Society or The American Psychiatric Association, has formally endorsed liraglutide for BED as of the date of this article. The absence of a guideline recommendation is meaningful context for an informed consent conversation.